Severe Hypernatremia Associated with Intravenous Fosfomycin: A Preventable Adverse Effect in the Intensive Care Setting


Abstract views: 32 / PDF downloads: 13

Authors

DOI:

https://doi.org/10.5281/zenodo.18462356

Abstract

Letter to Editor - No Abstract

References

Scavone C, Mascolo A, Bernardi FF, et al. Hypernatremia During Intravenous Treatment With Fosfomycin: A Retrospective Medical Record Review Study and an Analysis of Spontaneous Reports in the EudraVigilance Database. Front Pharmacol. 2022;13:844122. Published 2022 Mar 29. doi:10.3389/fphar.2022.844122

Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis. 2011;15(11):e732-e739. doi:10.1016/j.ijid.2011.07.007

Marx K, Malmström N, Quast M, et al. Monitoring Plasma Concentrations of Intravenously Administered Fosfomycin to Prevent Drug-Related Adverse Events: A Retrospective Observational Study. Antibiotics (Basel). 2025;14(6):548. Published 2025 May 27. doi:10.3390/antibiotics14060548

Sürmelioğlu N, Çetinkaya F, Gök MG, Aydın K, Özcengiz D. Intravenous fosfomycin therapy induced hypernatremia and hypokalemia in critically ill patients: a cross-sectional study. Flora. 2023;28(3):527-531. doi:10.5578/flora.20239724

Downloads

Published

2026-02-03

How to Cite

Akgül, A., & Koç, N. S. (2026). Severe Hypernatremia Associated with Intravenous Fosfomycin: A Preventable Adverse Effect in the Intensive Care Setting. Journal of European Internal Medicine Professionals, 4(1), 41–42. https://doi.org/10.5281/zenodo.18462356

Issue

Vol. 4 No. 1 (2026): J Eur Int Med Prof

Section

Letter to Editor

Categories

License

Copyright (c) 2026 Arzu Akgül, Neriman Sıla Koç

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

All articles published in this journal are licensed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0).